期刊文献+

重组人干扰素α2b联合阴道用乳杆菌活菌胶囊治疗HPV感染对患者HPV转阴及炎症因子的影响

Effect of Recombinant Human Interferon α2b Combined with Lactobacillus Live Capsule for Vaginal Treatment of HPV Infection on HPV Negative Transformation and Inflammatory Factors in Patients
原文传递
导出
摘要 研究分析重组人干扰素α2b联合阴道用乳杆菌活菌胶囊治疗HPV感染对患者HPV转阴及炎症因子的影响。选择2020年3月至2022年3月就诊于本院并接受治疗的135例宫颈HPV感染者作为研究对象,按照随机数字表法将入组患者分为研究组(n=67)及对照组(n=68),对照组患者给予重组人干扰素α2b阴道泡腾胶囊治疗,研究组患者在对照组治疗基础上联用阴道用乳杆菌活菌胶囊,比较两组患者治疗三个月后的临床效果,主要指标包括HPV转阴率、宫颈局部炎症因子改善情况以及阴道微生态环境的恢复情况。研究组患者HPV转阴率64.18%、治疗有效率91.04%,均显著高于对照组HPV转阴率47.06%、治疗有效率69.12%(P<0.05)。治疗后两组患者宫颈局部微生态环境中IL-4水平均显著下降,IL-12、IFN水平均显著上升(P<0.05),且研究组患者治疗后上述炎症因子的变化幅度较对照组更明显(P<0.05)。研究组微生态环境正常或恢复比例为91.04%,明显高于对照组61.76%(P<0.05)。重组人干扰素α2b联合阴道用乳杆菌活菌治疗宫颈HPV感染临床效果显著,有利于HPV转阴及恢复宫颈局部环境的微生态,改善炎症反应,避免宫颈病变的发生发展,能够作为常规治疗方案推向临床。 To study the effects of recombinant human interferon α2b combined with Lactobacillus live capsule for vaginal treatment of HPV infection on HPV negative transformation and inflammatory factors,a total of 135 patients with cervical HPV infection who received treatment in the hospital from March 2020 to March 2022 were selected as the study objects,and the patients were divided into control group(n=68)and treatment group(n=67)according to random number table method.Control group was treated with recombinant human interferon α2b vaginal effervescent capsule,observation group was treated with vaginal Lactobacillus live capsule on the basis of control group treatment.The clinical effects of the two groups were compared after 3 months of treatment,and the main indicators included HPV negative conversion rate,improvement of cervical local inflammatory factors and recovery of vaginal microecological environment.HPV negative conversion rate of 64.18% and effective rate of 91.04% in treatment group were significantly higher than 47.06% and effective rate of 69.12% in control group(P<0.05).After treatment,the levels of IL-4 in cervical local microecological environment were significantly decreased,and the levels of IL-12 and IFN were significantly increased in both groups(P<0.05).At the same time,the changes of the above inflammatory factors in the treatment group were more significant than those in the control group after treatment(P<0.05).The proportion of normal or restored microecological environment in treatment group was 91.04%,which was significantly higher than that in control group 61.76%(P<0.05).Recombinant human interferon α2b combined with live Lactobacillus in vagina has significant clinical effect in the treatment of cervical HPV infection,which can promote the negative transformation of HPV and the recovery of cervical local micro-ecological environment,improve inflammatory response,avoid the occurrence and development of cervical lesions,and can be promoted to the clinic as a routine treatment.
作者 程金丽 龚婷 CHENG Jin-li;GONG Ting(Pharmacy Department of Nanjing Yuhua Hospital,Nanjing 210000,China;Obstetrics and Gynecology Department of Nanjing Yuhua Hospital,Nanjing 210000,China)
出处 《药物生物技术》 CAS 2023年第6期591-595,共5页 Pharmaceutical Biotechnology
关键词 重组人干扰素Α2B 阴道用乳杆菌 联合治疗 人类乳头瘤病毒 临床疗效 炎症因子 Recombinant human interferon α2b Lactobacillus vaginalis Combined therapy HPV Clinical effect Inflammatory factor
  • 相关文献

参考文献18

二级参考文献168

  • 1张立岩,仵妍,张爱荣.人乳头瘤病毒感染与宫颈癌的关系[J].山东医药,2005,45(33):68-69. 被引量:4
  • 2高艳娥,郭金珠,张菊,宋天保,阎小君.宫颈癌患者HPV16型E6蛋白的表达纯化及血清抗体检测[J].癌症,2006,25(11):1374-1379. 被引量:5
  • 3张艳,李宁丽.人类乳头瘤病毒免疫致病机制[J].现代免疫学,2006,26(6):523-526. 被引量:15
  • 4Kang YH, Lee KA, Ryu C J, et al. Mitomycin C induces apoptosis via Fas/Fast dependent pathway and suppression of IL-18 in cer- vical carcinoma ceils [ J ]. Cancer Lett, 2006,237 ( 1 ) : 33-44.
  • 5Carvalho MO, Carestiato FN, Perdigao PH, et al. Human papillo- mavirus infection in Rio de Janeiro, Brazil: a retrospective study [J]. Braz J Infect Dis, 2005,9(5 ) : 398-404.
  • 6Bosch FX. Epidemiology of human papillomavirus infections: new options for cervical cancer prevention [J]. Salud Puhlica Mex, 2003,45 (Suppl 3 ) : 5326-5339.
  • 7Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The inter- national perspective [J]. Int J Cancer, 2004, 111 (2) : 278- 285.
  • 8Franeeschi S. The IARC commitment to cancer prevention the example of papillomavirus and cervical cancer [J]. Recent Re- suits Cancer Res, 2005,166 : 277-297.
  • 9Park TC, Kim C J, Koh YM, et al. Human papillmomavirus geno- typing by the DNA chip in the cervical neoplasia[J]. DNA Cell Biol, 2004,23 (2) : 119-125.
  • 10Walhoomers JM, Jacobs MV, Manos MM, et al. Human papillo- mavirus is a necessary cause of invasive cervical cancer world- wide[J]. J Pathol, 1999,189( 1 ) : 12-19.

共引文献329

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部